Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a treatment Hedgehog pathway inhibitors currently in development will also be discussed.
INTRODUCTION

Epidemiology
More than 2 million cases of nonmelanoma skin cancers were diagnosed in 2006 with approximately 80% of these being basal-cell carcinoma (BCC) [1] . Fortunately, BCC tumors rarely spread internally and are generally curable with local approaches such as surgical excision, radiotherapy, topical imiquimod, or photodynamic therapy [2] . However, in some cases BCC can progress to a point of significant local invasion such that surgical excision is not feasible or removal is associated with excessive morbidity or disfigurement. Additionally, some BCC tumors are not amenable to radiotherapy due to being in sensitive locations, or they can recur post-radiation therapy making further localized approaches not possible. Finally, although very rare, BCC can metastasize to distant sites of the body, which is considered a terminal condition. Patients with metastatic BCC have a median survival of around 8 months [3] . Locally, invasive BCC that is not amenable to surgical or radiation approaches or metastatic BCC are termed advanced BCC, and until recently, limited treatment options were available for patients with advanced BCC. No cytotoxic chemotherapy has been approved for the treatment of advanced BCC; however, agents such as cisplatin have been used for patients with metastatic BCC with varied results [4] .
Etiology
Similar to other skin malignancies, the risk of development of sporadic BCC has been linked to ultraviolet radiation exposure, skin type, family history, prior history of skin tumors, and immunosuppression [5] [6] [7] . However, a variety of hereditary syndromes can result in an increased risk of developing BCC tumors, including nevoid BCC syndrome, Bazex-Dupré-Christol syndrome, Rombo syndrome, Oley syndrome, and xeroderma pigmentosum [8] .
Nevoid BCC syndrome, which is also known as Gorlin-Goltz syndrome or simply Gorlin syndrome, is an autosomal-dominant condition that results in a varying array of defects including, but not limited to events such as macrocephaly, frontal bossing, congenital cataracts, hypertelorism, palmar pits, spina bifida, polydactyly, and hypogonadism [9] . This condition, which was first described in 1960, is also associated with the potential for development of numerous BCC tumors and medulloblastoma. A landmark finding published in 1996 described a germline mutation of the patched gene (PTCH), which is found on chromosome 9q22.3, and accounts for the findings in Gorlin syndrome [10, 11] . There have been a variety of types of mutations in the PTCH gene, which have been described including insertion, deletion, missense, nonsense, and splice site mutations [12] . Interestingly, sporadic cases of BCC can also have mutations in the PTCH or smoothened (SMO) gene with abnormal Hedgehog pathway signaling playing a dominant role in most cases [13] [14] [15] . It is translation of these basic science findings to the clinic which has resulted in a new generation of targeted therapeutics for the treatment of both sporadic BCC and congenital BCC syndromes.
THE HEDGEHOG GROWTH SIGNALING PATHWAY
The Hedgehog pathway plays a critical role in embryonic development and is not active in most adult tissues, with the exception of stem cells, hair follicles, and skin cells in which the pathway is important for cell maintenance [16] .
Key components of the Hedgehog pathway were first described in 1980 by NussleinVolhard et al. [17] . Hedgehog pathway signaling starts with the Hedgehog (Hh) ligand binding to a 12-pass transmembrane receptor known as PTCH, which is located in the primary cilium of the cell (Fig. 1) . In 1993, three mammalian homologs of the Hh ligand were described, including Sonic Hedgehog (named after the popular Sega videogame), and also Indian Hedgehog and Desert Hedgehog (both named after real hedgehog species) [18, 19] . The ''Hedgehog'' moniker was coined based on the description of Drosophila melanogaster (fruit fly) larvae, which took on the appearance of the spiky hedgehog when the gene was mutated.
In the absence of the Hh ligand, the PTCH receptor acts as a tumor suppressor by inhibiting the next protein in the pathway known as of activating a number of target genes, which can result in an oncogenic effect on the cell. Among the genes that are upregulated through Gli transcriptional activation are PTCH1 (provides negative feedback of pathway), Gli-1 (positive pathway feedback), and other gene pathways that aid in the survival of the cell, such as angiogenesis [20, 21] , cell cycle regulation [22] , and antiapoptosis pathways [23] . The Hedgehog pathway also conducts significant crosstalk with other molecules and pathways including p53, Wnt, PI3 K/aKT/mTOR, and retinoic acid. These interactions create a complex network, which may promote a variety of resistance mechanisms for drug targeting of this pathway. A variety of diseases have been linked to abnormal Hedgehog pathway signaling besides BCC, including medulloblastoma, hematologic malignancies, and other solid tumors [24] .
Cyclopamine, the first naturally occurring inhibitor of the Hedgehog pathway, was isolated from the Veratrum californicum (the California corn lily) plant [25] . Cyclopamine was named after its ability to induce cyclopia and holoprosencephaly in the progeny of animals that fed on the plant while pregnant, highlighting the alkaloid's role in impairing the Hedgehog pathway in developing embryos. [28] .
Most patients with metastatic BCC had three or more measurable target lesions (61%) with the most frequent sites of metastasis being lung and lymph nodes. Prior treatments for patients with metastatic disease included surgery (97%), radiation (58%), and systemic therapy (30%).
The objective response rate for patients with metastatic BCC was 30% upon independent review (45% site review). An additional 64% of metastatic patients had stable disease as best response on independent review (45% on site review), and 3% had progressive disease (6% site review). The median progression-free survival (PFS) was found to be 9.5 months for the metastatic cohort with a median duration of treatment of 10.0 months. In a subsequent presentation of the updated results of this study, median overall survival was found to be 24.1 months for patients with metastatic BCC [29] . Of the patients with locally advanced BCC, 38% were considered to have inoperable disease, with remainder considered to have surgically inappropriate due to multiple recurrences (25%), considerable chance for deformity or morbidity (51%), or both reasons (14%). In terms of radiotherapy, 21% had target lesions that were refractory to prior radiation, and 79% had lesions that were considered to be contraindicated or inappropriate for radiotherapy. The median objective response rate was found to be 43% upon independent review (60% site review). There were 38% of patients with stable disease (24% site review) and 13% with progressive disease (10% site review) as best response. The median PFS for locally advanced BCC patients was found to be 9.5 months with a median duration of treatment of 9.7 months. Of the patients who had biopsy to confirm response, 54% had no pathologic evidence of disease upon sampling.
Median overall survival for patients with locally advanced BCC has not been reached [29] .
Adverse events from vismodegib in this study included muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, loss of appetite, and diarrhea. There were 13 patients (12%) who discontinued treatment due to adverse events, with the most common reason being muscle spasms. Molecular analysis of mRNA expression of Gli-1 and PTCH2 were measured and shown to have similarly high levels in both the locally advanced and metastatic cohorts.
An expanded access study of vismodegib has also been conducted to help further understand the activity of the agent and allow access of the drug to locally advanced/metastatic BCC patients prior to FDA approval [29] . [29] .
Use of Vismodegib in Basal-Cell Nevus Syndrome
Vismodegib has also been prospectively evaluated in patients with basal-cell nevus syndrome (Gorlin syndrome) [30] . In a randomized, double-blind, placebo-controlled This study has highlighted several important points regarding the treatment of patients with basal-cell nevus syndrome with a Smo inhibitor.
Although active treatment with vismodegib was able to control the rate of new lesions and decrease the size of existing lesions, the treatment was intolerable for many patients, making long-term use challenging. Although the rate of new lesions after discontinuation of vismodegib was still lower than those in the placebo arm, the effect was much less prominent than when these patients were on active treatment. These findings confirm an inhibitory effect of Smo blockade on BCC tumor cell growth over time; however, few patients are likely to have a long-term benefit due to either primary resistance which develops in a small population of tumor cells or the toxicity ceiling of the drug prevents prolonged use and thus incomplete tumor cell kill. As Gorlin syndrome represents a lifelong disease with continuous potential for the development of BCC tumors, the ideal treatment would be one that is effective and tolerable enough for continued use (perhaps a topical therapy).
LDE225
Via cell-based high-throughput screening, LDE225 was identified as a selective, potent inhibitor of Smo, which is currently in clinical development for BCC and other cancer types [31] . It has been evaluated in a phase 1 dose-escalation study, which was reported at ASCO in 2010 [32] . In this study, patients with as in nevoid BCC syndrome, the use of topical LDE225 appears to be a rational approach as it avoids systemic exposure that predisposes to more side-effects. [35] . In a patient with medulloblastoma with a known PTCH mutation, the initial response to vismodegib was seen with subsequent progression of disease [36] . 
OTHER Smo Inhibitors in Development
PRACTICAL CONSIDERATIONS FOR THE USE OF VISMODEGIB
ACKNOWLEDGMENTS
There was no funding received or sponsorship for the manuscript. Dr. Cowey is the guarantor 
